Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The messenger RNA vaccine and drug developer's latest round includes a $171m investment by strategic partner GlaxoSmithKline.

UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

Mingdu Intelligent, backed by three Chinese academic institutions, has increased its funding haul to at least $26m.

Vesigen has attracted Leaps by Bayer to commercialise drug delivery technology invented by Quan Lu at Harvard School of Public Health.

GV had led an oversubscribed series D round for the gene therapy developer that also featured Illumina Ventures and SoftBank Vision Fund II.

Pfizer and Chiesi-backed genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

Leaps by Bayer has co-led a $28.5m series A round disclosed when precision medicine startup Vesigen Therapeutics publicly launched.

Delta Dental Washington Seed Fund was among the participants in a $10.8m round for the pelvic bone implant developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.